Members-only Site   |   Print Page   |   Contact Us   |   Sign In   |   Register
IACP Corporate Partner Spotlight: PCCA
Share |

 

 

PCCA Launches New, Exclusive Base – XemaTop™ (PCCA #30-4891)


Designed for Formulations Targeting Patients with Eczema, Psoriasis and Xerosis

More than 24.8 million Americans live with moderate to severe eczema1 and psoriasis.2

Using the power and synergy of natural boswellic acid, avenanthramides from oats, phosphatidylglycerol and elegant film formers, XemaTop delivers and improves the action of common active pharmaceutical ingredients (APIs) used in formulations for patients with eczema, psoriasis and xerosis.

 

XemaTop nourishes and replenishes the lamellar bilayers of the skin and helps restore health into the skin’s barrier to reduce the appearance of redness and irritation.

 

BENEFITS:

 

•    Replenishes the lipids within the skin
•    Nourishes the skin’s structural integrity
•    Improves the appearance of red and irritated skin

 

COMMONLY COMPOUNDED WITH:

 

•    Corticosteroids
•    Vitamin D and derivatives
•    Vitamin E and derivatives
•    Cyanocobalamin
•    Zinc pyrithione

 

USED AS A VEHICLE IN COMPOUNDS FOR THE FOLLOWING SPECIALTIES:

 

•    Dermatology
•    Anti-aging
•    Family practice
•    Pediatrics

 

IN OUR CONTROLLED STUDY:

 

EFFECTS OF APPLYING VARIOUS VEHICLES AND FORMULATIONS TO PSORIATIC TISSUE (PART 1)

 

Results of this study show that various formulations have the ability to significantly inhibit the production of interleukin IL-6 in vitro, when used alone and in combination with mometasone furoate and calcitriol. The reduction in IL-6 levels within psoriasis tissues could potentially lead to a reduced inflammatory response and cellular proliferation associated with psoriasis. Results also showed that XemaTop is superior to the reference product as a vehicle for the delivery of active pharmaceutical ingredients (mometasone furoate and calcitriol) with anti-inflammatory and antiproliferative properties. This promising data suggests that XemaTop may be a valuable base for formulations targeting these types of patients.

 

Click here for the full study.

 

We take your success personally. As the compounding industry leader for the past 35 years, PCCA supplies everything you need to deliver personalized medicine that makes a difference for your patients and your business. Learn more at www.pccarx.com/about.

 

These statements have not been evaluated by the Food and Drug Administration. Every effort has been made to accurately represent scientific research that utilized PCCA products. Results of studies or case reports in these materials are not to be interpreted as a promise, guarantee or claim of therapeutic efficacy or safety. The information is provided for educational purposes only. It is not intended to replace or substitute for conventional medical care, or encourage its abandonment.

 

References:

 

1. Hanifin JM, Reed ML. A population-based survey of eczema prevalence in the United States. Dermatitis. 2007 Jun;18(2):82-91.

 

2. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014; 70(3):512.

Association Management Software Powered by YourMembership  ::  Legal